Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most expiry-date and label-reading/storage/hold-time claims are not supported by the provided FDA label excerpts. Several safety/handling recommendations about expired vials and unlabeled product are not addressed in the supplied sections, making the response largely unsupported for label alignment.
Category Scores
Accurate Statements
After reconstitution (and sometimes after further dilution in an IV bag), usable time depends on the specific product, concentration, diluent, and storage conditions.
Not determinable from the provided prescribing information excerpts; no reconstitution/IV bag hold-time or concentration/diluent/stability statements are included in the supplied label text.
Unsupported Statements
Ertapenem has an expiry date printed on the product label.
The provided excerpts do not mention expiry dates or label typography.
The printed expiry date on ertapenem is the manufacturer’s stated 'do not use after' time for the unopened product under the labeled storage conditions.
No storage, expiry-date definition, or 'do not use after' language is included in the supplied excerpts.
The expiry date for ertapenem can usually be found on the vial/box label near 'EXP' or 'Expiration'.
No label-location guidance for expiry dates is present in the provided excerpts.
The printed expiry date applies to the unopened/unreconstituted ertapenem product.
No guidance on whether expiry applies pre- vs post-reconstitution is included in the provided excerpts.
After reconstitution, the usable time of ertapenem depends on the specific product.
No reconstitution/usable-time/hold-time information is included in the provided excerpts.
After reconstitution, the usable time of ertapenem depends on concentration.
No reconstitution/usable-time stability information is included in the provided excerpts.
After reconstitution, the usable time of ertapenem depends on diluent.
No reconstitution/diluent-related hold-time or stability information is included in the provided excerpts.
After reconstitution, the usable time of ertapenem depends on storage conditions.
No post-reconstitution storage/hold-time information is included in the provided excerpts.
The 'after reconstitution' hold times for ertapenem are typically given in the prescribing information or pharmacy preparation instructions.
The supplied excerpts do not contain any reconstitution hold-time/stability statements.
The only reliable way to confirm the expiry for a specific ertapenem bottle is to read the label on that exact package.
The provided excerpts do not address expiry verification methods.
The lot number and expiry date for ertapenem are tied to that manufacturing run.
No lot/expiry relationship is described in the provided excerpts.
If a ertapenem vial is past its labeled expiry date, it should not be used.
The provided excerpts do not address what to do with expired product.
If the ertapenem label is unreadable or missing, discarding it and using a properly labeled replacement from stock is the safest option.
The provided excerpts do not provide guidance on unreadable/missing labels or discarding procedures.
Contradictions
Important Omissions
Any label-supported statements regarding reconstitution, dilution, and post-reconstitution hold times/stability; any label-supported statements regarding expiry dating, storage conditions tied to expiry, or handling of expired/unreadable-labeled product.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple practical handling/expiry claims and recommendations not supported by the provided FDA label excerpts. If incorrect, these could lead to misuse of product or reliance on non-labeled criteria. However, the response does not introduce dosing/contraindication contradictions from the supplied label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Expiry/reconstitution/hold-time/label-handling claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to sections present in the supplied label (e.g., indicated populations, dosing/durations, contraindications, key warnings such as seizures and valproic acid interaction, adverse reactions, and renal dosing). For expiry and post-reconstitution hold times, quote only text from the actual label sections covering storage/handling or preparation/stability; if not provided, avoid definitive statements.